- Home
- DBD vs DYN Comparison
DBD vs DYN Comparison
Compare DBD & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBD | DYN |
|---|---|---|
| Founded | 1859 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DBD | DYN |
|---|---|---|
| Price | $73.22 | $18.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 15 |
| Target Price | ★ $90.00 | $37.87 |
| AVG Volume (30 Days) | 306.5K | ★ 2.0M |
| Earning Date | 05-14-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 677.27 | N/A |
| EPS | ★ 2.54 | N/A |
| Revenue | ★ $3,805,700,000.00 | N/A |
| Revenue This Year | $3.56 | N/A |
| Revenue Next Year | $3.25 | N/A |
| P/E Ratio | $29.59 | ★ N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $34.88 | $7.01 |
| 52 Week High | $84.46 | $25.00 |
Technical Indicators
Market Signals| Indicator | DBD | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 40.74 | 56.40 |
| Support Level | $67.60 | $16.34 |
| Resistance Level | $84.44 | $20.10 |
| Average True Range (ATR) | 2.71 | 1.15 |
| MACD | -1.16 | 0.51 |
| Stochastic Oscillator | 8.29 | 68.49 |
Price Performance
Historical ComparisonAbout DBD Diebold Nixdorf Incorporated
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.